Tag: dermatology

May 9, 2018

Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update

Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs...
May 9, 2018

miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides

miRagen Therapeutics (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced new interim data...
May 7, 2018

Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w)

Aclaris Therapeutics (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase by dermatologists in the...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 6, 2018

Is this the Next Botox? Evolus’s Phase 3 Study Met Primary Endpoints

Botox has long been one the best solutions for smoothing wrinkle lines, managing skin breakouts, lifting lips and more, but...
April 6, 2018

Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution

Aclaris Therapeutics (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs...
April 5, 2018

Evolus Phase III European – Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint

Evolus (NASDAQ:EOLS) a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced...